Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Current Leases (2021 - 2025)

Sutro Biopharma's Current Leases history spans 5 years, with the latest figure at $8.0 million for Q3 2025.

  • For Q3 2025, Current Leases rose 10.51% year-over-year to $8.0 million; the TTM value through Sep 2025 reached $8.0 million, up 10.51%, while the annual FY2024 figure was $7.5 million, 16.51% up from the prior year.
  • Current Leases for Q3 2025 was $8.0 million at Sutro Biopharma, down from $8.1 million in the prior quarter.
  • Across five years, Current Leases topped out at $8.1 million in Q2 2025 and bottomed at $1.0 million in Q4 2021.
  • The 5-year median for Current Leases is $6.2 million (2023), against an average of $5.2 million.
  • The largest annual shift saw Current Leases soared 429.82% in 2023 before it rose 10.51% in 2025.
  • A 5-year view of Current Leases shows it stood at $1.0 million in 2021, then soared by 342.14% to $4.6 million in 2022, then soared by 40.02% to $6.4 million in 2023, then grew by 16.51% to $7.5 million in 2024, then increased by 6.42% to $8.0 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's Current Leases are $8.0 million (Q3 2025), $8.1 million (Q2 2025), and $7.8 million (Q1 2025).